Search filters
Filters
Clear AllPhase
-
183
-
156
-
2
-
194
-
1
-
152
-
17
-
402
Age
-
1246
-
593
Gender
-
29
-
49
-
3
-
1172
Virtual Trials
-
1247
-
6
New Trials
-
4
-
1249
Loading...
Found 1253 All Conditions trials
A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
This study seeks to roll over subjects from ISIS 678354-CS3 (the index study; Penn IRB#850921). Patients will receive drug at the dose of 80 mg every 4 weeks (or 50 mg every-4-weeks if their dose was permanently reduced from 80 mg to 50 mg (ISIS 678354 or placebo) in the …
The COvid19 VaccinE Response in Rheumatology Patients (COVER)
This study is designed to evaluate the efficacy and safety of SARS-CoV-2 vaccines in patients with autoimmune conditions and to evaluate the impact of different immunomodulatory therapies on vaccine response. Adults with psoriatic arthritis (PsA), axial spondyloarthritis (SpA) and rheumatoid arthritis (RA) will be enrolled. The study involves data and …
A 6-month prospective randomized double-blind placebo-controlled clinical trial investigating the efficacy safety and tolerability of two different doses of buntanetap or placebo in patients with early Parkinsons disease
A double-blind study to investigate efficacy and safety of buntanetap compared with placebo in participants with early PD
Alzheimers Disease Neuroimaging Initiative 4
The aim of the Alzheimers Disease Neuroimaging Initiative (ADNI) has been to validate biomarkers for Alzheimers disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic …
Assessing Diagnostic Predictors of Airway Collapse in patients with Obstructive Sleep Apnea
This study is a multicenter study of up to 300 subjects diagnosed with OSA who are being evaluated for airway surgery, including hypoglossal nerve stimulation. Subjects will undergo standard evaluation for airway surgery as part of standard of care. In addition, a simple, non-invasive measurement of the pharyngeal width (PW) …
An Open-label Extension Study of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis
This study is the OLE of the Main study currently ongoing. Targeted population are those individuals who completed the original study. Study procedures include physical exams, safety labs, ECGs, breathing tests, and questionnaires.
UPCC 38422: Phase 3 Multicenter Double-Blind Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant
A study to evaluate posoleucel (ALVR105); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus. We would like to rely on WCG as the IRB of record for this study.
A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once daily for the Treatment of HIV-1 Infection in subjects Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study
This trial is testing doravirine/islatravir (also known as MK-8591A or DOR/ISL) in people living with HIV-1 who have participated in another Merck-sponsored trial of DOR/ISL. The main purpose of this trial is to test the safety and efficacy of DOR/ISL and give patients continued access to DOR/ISL through this rollover …
A Safety and Feasibility Single-Arm Study of a Novel Catheter Thrombectomy Device For the Treatment of Pulmonary Embolism (ENGULF)
Please see section 4 of the full protocol Please see section 4 of the full protocol Please see section 4 of the full protocol
A Phase 1 Open-Label Safety Pharmacokinetic and Preliminary Efficacy Study of STRO-002 an Anti-Folate Receptor alpha (FolR) Antibody Drug Conjugate (ADC) in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)
To evaluate the safety and tolerability of STRO-002/bevacizumab as a combination therapy. To further evaluate the toxicity and tolerability of STRO-002/bevacizumab in patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) To characterize the PK of STRO-002 when administered with bevacizumab To assess the immunogenic potential …
Please choose between Voice or SMS based delivery of verification code
or